Autoantibodies to Thrombomodulin: Development of an Enzyme Immunoassay and a Survey of their Frequency in Patients with the Lupus Anticoagulant

Summary

In order to investigate the possibility that autoantibodies to thrombomodulin (TM) may exist in patients with the lupus anticoagulant (LA) and perhaps be implicated in the pathogenesis of recurrent thrombosis seen in such patients, we developed an enzyme-immunoassay to screen serum samples for anti-human TM activity. The major technical problem encountered in developing this assay was to reduce the non-specific binding of serum components from both the LA positive and the negative population. Considerable reduction of non-specific binding was achieved by use of a phosphate/citrate buffer at pH 8.0 and the use of an optimal sample dilution of 1/40. In addition, samples were always tested in parallel in blank wells and results are expressed as an OD ratio. Samples from 113 patients with the LA were assayed and compared to 78 patients referred for LA testing but found to be negative. The mean OD values for the LA positive patients (± SD) was 1.36 (0.44) with a range of 0.78-2.57. This was virtually identical to the values for the LA negative population (1.38 ± 0.40, range 0.76-2.77). The results of this study indicate that there is no evidence for the presence of a significant autoantibody activity to TM in patients with the LA when compared to LA negative patients. If such autoantibodies do exist their frequency must be quite low.

• References

• 1 Lechner K. Lupus anticoagulants and thrombosis. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Amout J. (eds) Leuven University Press; Leuven: 1987. pp 525-547
• 2 Espinoza LR, Hartman RC. Significance of the lupus anticoagulant. Am J Hematol 1986; 22: 331-337
• 3 Feinstein DL. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-1350
• 4 Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-489
• 5 Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid antibodies. Clin Rheumatol Dis 1985; 11: 591-609
• 6 Friedman KD, Marlar RA, Gill JC, Endres-Brooks J, Montgomery RR. Protein S deficiency in patients with the lupus anticoagulant (abstr). Blood 1986; 68: 1210
• 7 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62: 1099
• 8 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-1194
• 9 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralises the enhancing effect of phospholipid on purified endothelial thrombomodulin activity - A mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
• 10 Clouse LH, Comp PC. The regulation of haemostasis: the protein C system. N Engl J Med 1986; 314: 1298-1304
• 11 Marder VJ. Molecular bad actors and thrombosis. N Engl J Med 1984; 310: 588-589
• 12 Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1987; 71: 728-733
• 13 Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M, Alarcon-Segovia D. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to activity of anticardiolipin antibody with thrombomodulin. J Rheumatol 1989; 16: 381-383
• 14 Gibson J, Starling E, Date L, Rickard KA, Kronenberg H. Simplified screening procedure of detecting lupus inhibitor. J Clin Pathol 1988; 41: 226-228
• 15 Salem HH, Maruyama I, Ishii H, Majerus PW. Isolation and characterisation of thrombomodulin from human placenta. J Biol Chem 1984; 259: 12246-12251
• 16 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029